## Single Prophylactic Antibiotic Dose for Total Knee Arthroplasty Resulting in No Increased Risks in Prosthetic Joint Infection

Yu-Tung Lan, Ya-Wen Chen<sup>1</sup>, Ruijia Niu<sup>2</sup>, David C Chang<sup>3</sup>, David A Mattingly, Carl T Talmo<sup>2</sup>, Eric Louis Smith, Brian Hollenbeck

<sup>1</sup>MGH, <sup>2</sup>New England Baptist Hospital, <sup>3</sup>Massachusetts General Hospital, Harvard Medical Sch

INTRODUCTION: There has been conflicting evidence whether extended oral antibiotic prophylaxis can reduce prosthetic joint infection (PJI) after total knee arthroplasty (TKA). In this study, we aim to investigate the efficacy of four common antibiotic prophylactic regimens to prevent PJI.

METHODS: In this observational study, 8,676 patients undergoing outpatient TKA between 2017-2019 were examined. Patients receiving single-dose prophylactic antibiotic (n= 2,224) were compared to patients with multiple-dose (n= 3,617), multiple types (n= 2,468), and extended oral prophylaxis (n= 367). Patients who developed 90-day and one-year PJI were identified. Additionally, we compared the PJI rate between those with and without extended oral prophylaxis among selected high-risk patients. Multivariate regression models were performed to adjust for potential confounders.

RESULTS: Overall, 75 patients (0.9%) developed 90-day PJI. Compared to patients with single-dose prophylaxis, those with multiple-dose were not associated with a lower PJI risk (OR= 1.50, 95% CI [0.74, 3.03]); neither were patients with multiple types (OR= 1.90, 95% CI [0.93, 3.89]) nor patients with extended oral prophylaxis (OR= 1.82, 95% CI [0.58, 5.89]). Findings were similar for high-risk patients, where extended oral prophylaxis was not associated with a decreased PJI rate when compared to no oral prophylaxis (OR= 1.60, 95% CI [0.49, 5.28]).

DISCUSSION AND CONCLUSION: More than a single dose of prophylactic antibiotic was not associated with a reduced PJI risk after TKA. Similarly, for TKA patients with high risks of infection, extended oral prophylaxis did not decrease the PJI

	(N=8676)	Patients with single dose of IV autibiodos <sup>2</sup> (N= 2224)	Fasions with multiple doses of the same type IV antibiotics (N=3617)	Patients with multiple types" of IV authories (N= 2468)	Patients with both IV and extended end antibiories <sup>109</sup> (N=367)	Pvalse
Proethetic isint infection, (%)						
	802(87)	65.6 (9.7)	58.5 (7.5)	59.8 (8.6)	29.1 (8.1)	+0.000
History of comorbidities						
Diabetes with Imperativeenia, (%)					22 (8.0%)	0.95
						8.60
		287 (12.9%)	515 (14.2%)	366 (14,8%)		
				275 (11.25)		<0.000
Need orientation of MISA or MISSA, PGI	10 (13%)	59 (2.2%)	41 (1.7%)	24 (1.0%)	140,7%)	-0.800
Infection within 50-days prior to						0.04
TKA, (%) Abbreviation SD: mandarl-deviation, (V)			109 (4.7%)			

25 years			P-value
Moliphi chairs of the same upper Y artiflutions   1.50 (1.5, 1.0)   0.5 (1			
Mapier press   TV antibines   100 (0.1) xin   0.10	Single dose of IV antibiotics*	1 (reference group)	
Boh   Val annoher attributos**   128(28,59)   0.10			
Apr	Multiple types <sup>55</sup> of IV antibiotics		
25 years	Both IV and extended oral antibiotics***	1.82 (0.58, 5.89)	0.30
55-65 ymm	Nge		
***/**System         0.85 (30.), 1.09         0.5           Confer         1         0           Final         0.1 (20.0)         0           Result         0.4 (20.0)         0           Result         0.4 (20.0)         0           Result         0.4 (20.0)         0           Result         0.4 (20.0)         0           A horizonta dises         1.3 (20.0)         0           Stations (Mms         3.0 (10.0)         0           Smaking         1.1 (20.4)         2.0           Associated control (20.0)         2.0 (20.0)         0           Smaking         1.1 (20.4)         2.0           Associated (20.0)         0.0         0           Associated (20.0)         0.0         0           Associated (20.0)         0.0         0         0           Associated (20.0)         0.0         0         0         0           Associated (20.0)         0.0         0         0         0         0           Associated (20.0)         0.0         0         0         0         0         0         0         0           Associated (20.0)         0.0         0         0         0		1 (reference group)	
Gender			
Mole Theretal         1 (offermore group)         cm           History of countribution         0.41 (20.5, 00.2)         4.00           History with hyperglycomia         131 (03.2, 0.2)         1.00           Albatics with hyperglycomia         131 (03.2, 0.2)         1.00           Substance Manager         3.09 (10.8, 8.5)         0.0           Mental deathy with MILE-04         2.921 (70.3)         0.0           Sanking         1.11 (03.4, 2.2)         1.00           Interface on with 10 are greater WISA         0.76 (03.2, 2.4)         1.00		0.45 (0.20, 1.00)	0.05
Ferrale         0.43 (0.25, 0.09)         <0.000           Hillstry of omorrhidities         0.21 (0.25, 2.02)         0.54           Dalseles with hyperplecusis         0.21 (0.25, 2.02)         0.54           Autonimumo diseases         1.31 (0.17, 2.29)         0.75           Substance albuse         2.20 (1.15, 5.00)         0.001           Medial declay with BIME-0         2.20 (1.15, 5.00)         0.001           Nation Constraints of MISSA or MISSA         2.60 (1.04, 11.21)         0.17           Infection within, Davis or the TKA         0.76 (0.42, 2.44)         0.5			
History of comorbidities   0.73 (0.25, 2.02)   0.54			
Diabetes with hyperplycensis         0.73 (0.5, 202)         0.5           Actionimus diseases         1.33 (0.71, 2.59)         0.37           Substance brase         3.094 (1.6, 8.57)         0.47           Morbid deesity with BME-60         2.93 (1.76, 5.01)         -0.00           Smalling         1.00 (1.6, 2.22)         0.00           Importance of MRSA or MSSA         1.00 (0.4, 2.22)         0.07           Importance of MRSA or MSSA         0.00 (0.24, 2.24)         0.05           OF (0.04, 2.24)         0.05         0.07 (0.24, 2.24)         0.05		0.43 (0.26, 0.69)	<0.001
Autoimment disease			
Substance abuse         3.09 (1.08, 8.87)         0.04           Morbid obesity with BME≥40         2.93 (1.70, 5.00)         <0.001			
Morbid obesity with BME>40         2.93 (1.70, S.03)         <0.001           Smoking         1.11 (0.54, 2.29)         0.77           Nead colonization of MRSA or MSSA         2.69 (0.64, 11.23)         0.17           Infection within 10 days more to TKA         0.76 (0.24, 2.44)         0.65			
Smoking         1.11 (0.54, 2.29)         0.77           Nasal colonization of MRSA or MSSA         2.69 (0.64, 11.23)         0.17           Infection within 30 days prior to TKA         0.76 (0.24, 2.44)         0.65			
Nasal colonization of MRSA or MSSA 2.69 (0.64, 11.23) 0.17 Infection within 30 days prior to TKA 0.76 (0.24, 2.44) 0.65			
Infection within 30 days prior to TKA 0.76 (0.24, 2.44) 0.65			
Infection within 30 days prior to TKA 0.76 (0.24, 2.44) 0.65			
	Infection within 30 days prior to TKA		
	ethicillin-resistant Staphylococcus aureus, MSSA: methicilli Prophylactic IV antibiotics examined in the study included Co		

	Overall high- risk patients (N=3335)	Patients without oral antibiotics (N= 3187)	Patients with oral antibiotics <sup>45</sup> (N= 148)	P-valu
Prosthetic joint infection, (%)	41 (1.250)	38 (1.2%)	3 (2.0%)	0.37
Age, mean (SD)	59.1 (8.4)	59.2 (8.5)	57.3 (7.3)	< 0.01
Female, (%)	2068 (62.0%)	1986 (62.3%)	82 (55.4%)	0.09
History of comorbidities				
Diabetes with hyperalycemia, (%)	512 (15.4%)	490 (15.4%)	22 (14.9%)	0.87
Chronic kidney disease stage 5, (%)	8 (0.2%)	8 (0.3%)	0 (0%)	0.54
Autoimmune disease, (%)	1221 (36.6%)	1168 (36.6%)	53 (35.8%)	0.84
Substance abuse, (%)	119 (3.6%)	115 (3.6%)	4 (2.7%)	0.56
Mosted obusing with BME:40, (74)	939 (28.2%)	894 (28.174)	42 (20.4%)	0.55
Smoking, (%)	722 (21.6%)	693 (21.7%)	29 (19.6%)	0.53
Nasal colonization of MRSA or MSSA, (%)	116 (3.5%)	115 (3.6%)	1 (0.7%)	0.06
Infection within 30 days prior to TKA, (%) Abbreviation SD: standard deviation, IV:	475 (14.2%)	450 (14.1%)	25 (16.9%)	0.35

	OR (95% CT)	P-value
Antibiotic regimens Without oral antibiotics With oral antibiotics	1 (reference group) 1.60 (0.49, 5.28)	0.44
Apr ≤55 years >55-65 years >65 years	1 (reference group) 0.71 (0.37, 1.38) 0.52 (0.19, 1.43)	0.32 0.21
Gender Male Female	1 (reference group) 0.48 (0.25, 0.89)	0.02
Number of risk factors  1 risk factor  2 risk factors >3 risk factors	1 (reference group) 1.14 (0.52, 2.51) 1.96 (0.46, 8.36)	0.74 0.36